JP2022542562A5 - - Google Patents

Info

Publication number
JP2022542562A5
JP2022542562A5 JP2022504132A JP2022504132A JP2022542562A5 JP 2022542562 A5 JP2022542562 A5 JP 2022542562A5 JP 2022504132 A JP2022504132 A JP 2022504132A JP 2022504132 A JP2022504132 A JP 2022504132A JP 2022542562 A5 JP2022542562 A5 JP 2022542562A5
Authority
JP
Japan
Application number
JP2022504132A
Other languages
Japanese (ja)
Other versions
JP2022542562A (ja
JPWO2021016430A5 (https=
JP7764363B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/043223 external-priority patent/WO2021016430A1/en
Publication of JP2022542562A publication Critical patent/JP2022542562A/ja
Publication of JPWO2021016430A5 publication Critical patent/JPWO2021016430A5/ja
Publication of JP2022542562A5 publication Critical patent/JP2022542562A5/ja
Priority to JP2025177461A priority Critical patent/JP2026012822A/ja
Application granted granted Critical
Publication of JP7764363B2 publication Critical patent/JP7764363B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022504132A 2019-07-23 2020-07-23 mRNA担持脂質ナノ粒子の安定性組成物および作製のプロセス Active JP7764363B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025177461A JP2026012822A (ja) 2019-07-23 2025-10-22 mRNA担持脂質ナノ粒子の安定性組成物および作製のプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877597P 2019-07-23 2019-07-23
US62/877,597 2019-07-23
PCT/US2020/043223 WO2021016430A1 (en) 2019-07-23 2020-07-23 Stable compositions of mrna-loaded lipid nanoparticles and processes of making

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025177461A Division JP2026012822A (ja) 2019-07-23 2025-10-22 mRNA担持脂質ナノ粒子の安定性組成物および作製のプロセス

Publications (4)

Publication Number Publication Date
JP2022542562A JP2022542562A (ja) 2022-10-05
JPWO2021016430A5 JPWO2021016430A5 (https=) 2023-07-31
JP2022542562A5 true JP2022542562A5 (https=) 2023-07-31
JP7764363B2 JP7764363B2 (ja) 2025-11-05

Family

ID=72088362

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504132A Active JP7764363B2 (ja) 2019-07-23 2020-07-23 mRNA担持脂質ナノ粒子の安定性組成物および作製のプロセス
JP2025177461A Pending JP2026012822A (ja) 2019-07-23 2025-10-22 mRNA担持脂質ナノ粒子の安定性組成物および作製のプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025177461A Pending JP2026012822A (ja) 2019-07-23 2025-10-22 mRNA担持脂質ナノ粒子の安定性組成物および作製のプロセス

Country Status (11)

Country Link
US (2) US12144871B2 (https=)
EP (1) EP4003311A1 (https=)
JP (2) JP7764363B2 (https=)
KR (1) KR20220038365A (https=)
CN (1) CN114401748A (https=)
AU (1) AU2020315962B2 (https=)
BR (1) BR112022001192A2 (https=)
CA (1) CA3146675A1 (https=)
IL (2) IL289944A (https=)
MX (1) MX2022000934A (https=)
WO (1) WO2021016430A1 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
US20230285297A1 (en) * 2020-01-31 2023-09-14 Modernatx, Inc. Methods of preparing lipid nanoparticles
WO2021231901A1 (en) * 2020-05-15 2021-11-18 Translate Bio, Inc. Lipid nanoparticle formulations for mrna delivery
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
EP4294450B1 (en) * 2021-02-16 2026-02-04 The Johns Hopkins University Methods for preparation of plasmid dna/lipid particles with defined size for in vitro and in vivo transfection
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
US20240238211A1 (en) * 2021-04-23 2024-07-18 Modernatx, Inc. Isoquinoline-stabilized lipid nanoparticle formulations
EP4326227A1 (en) * 2021-04-23 2024-02-28 ModernaTX, Inc. Stabilized formulations
GB202108444D0 (en) * 2021-06-14 2021-07-28 Imperial College Innovations Ltd Sub-micron particle
MX2024002726A (es) 2021-09-03 2024-03-20 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
KR20230053998A (ko) 2021-10-15 2023-04-24 (주)지노믹트리 mRNA 발현을 위한 유전자 구조체
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
MX2024005462A (es) 2021-11-05 2024-05-22 Sanofi Sa Vacuna de arn del virus respiratorio sincitial.
AU2022399571A1 (en) 2021-11-30 2024-07-11 Sanofi Pasteur Inc. Human metapneumovirus vaccines
US20250067729A1 (en) * 2021-12-15 2025-02-27 ModrnaTX, Inc. Determination of encapsulation efficiency of lipid nanoparticles
WO2023111262A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
CN116549626A (zh) * 2022-01-27 2023-08-08 深圳瑞吉生物科技有限公司 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
EP4479097A1 (en) 2022-02-15 2024-12-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating tear film composition to treat corneal defects
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
EP4531819A2 (en) 2022-05-25 2025-04-09 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
EP4565209A1 (en) 2022-08-04 2025-06-11 Sanofi Pasteur Inc. Quantitative assessment of rna encapsulation
WO2024057237A1 (en) * 2022-09-16 2024-03-21 Pfizer Inc. Lipid nanoparticles
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
CN120202025A (zh) * 2022-11-03 2025-06-24 深圳鸿生生物科技有限公司 用于增强核酸递送的组合物
WO2024094881A1 (en) 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination
US20240165213A1 (en) * 2022-11-21 2024-05-23 Avstera Therapeutics Corp. mRNA COMPOSITION FOR PREVENTING AND TREATING CANCER
WO2024133515A1 (en) 2022-12-20 2024-06-27 Sanofi Rhinovirus mrna vaccine
AR132053A1 (es) 2023-03-02 2025-05-21 Sanofi Pasteur Composiciones para su uso en el tratamiento de clamidia
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
US20250009865A1 (en) 2023-05-10 2025-01-09 Sanofi Combination respiratory mrna vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
EP4713003A1 (en) 2023-05-17 2026-03-25 Institut National de la Santé et de la Recherche Médicale Lipc variant in the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease
EP4722368A1 (en) 2023-05-26 2026-04-08 Samsung Biologics Co., Ltd. Novel nucleic acid construct comprising poly(a) tail having secondary or tertiary structure and uses thereof
KR20250018367A (ko) 2023-07-28 2025-02-05 한국과학기술원 히스톤 코드 리더 도메인을 포함하는 폴리펩티드 및 이의 용도
US20250090650A1 (en) 2023-09-06 2025-03-20 Sanofi Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
US12343429B2 (en) 2023-10-05 2025-07-01 Nanovation Therapeutics Inc. Method of delivery of DNA or RNA cargo unshielded lipid nanoparticles and compositions thereof
WO2025186293A1 (en) 2024-03-06 2025-09-12 Institut National de la Santé et de la Recherche Médicale Chmp2b mutants for use for treating infection
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025210592A1 (en) 2024-04-05 2025-10-09 Sanofi Pasteur Inc. Muscle cell lnp-mrna quality control assays
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026027730A1 (en) 2024-07-31 2026-02-05 Sanofi Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof
WO2026033123A1 (en) 2024-08-08 2026-02-12 Sanofi Pasteur Inc. Lipid nanoparticle formulations for mrna delivery
WO2026052773A1 (en) 2024-09-06 2026-03-12 Sanofi Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
CN104119242B (zh) 2008-10-09 2017-07-07 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
MX342785B (es) 2009-06-10 2016-10-12 Alnylam Pharmaceuticals Inc Formulacion mejorada de lipido.
EP3354644A1 (en) 2011-06-08 2018-08-01 Translate Bio, Inc. Cleavable lipids
SG10201605512WA (en) 2011-07-06 2016-09-29 Novartis Ag Oil-in-water emulsions that contain nucleic acids
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, n-말단 상에 관능화된 아미노산 유도체
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
ES2762873T3 (es) 2012-03-29 2020-05-26 Translate Bio Inc Lípidos catiónicos ionizables
PL3467108T3 (pl) 2013-03-14 2024-09-30 Translate Bio, Inc. Sposoby oczyszczania informacyjnego rna
MX2016005238A (es) * 2013-10-22 2016-08-12 Shire Human Genetic Therapies Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
PT3134506T (pt) 2014-04-25 2019-10-31 Translate Bio Inc Métodos de purificação de rna mensageiro
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
SMT202200502T1 (it) 2014-06-25 2023-01-13 Acuitas Therapeutics Inc Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
BR112016030852A2 (pt) 2014-07-02 2018-01-16 Shire Human Genetic Therapies encapsulação de rna mensageiro
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US20180000953A1 (en) 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016118725A1 (en) 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
ES2949540T3 (es) 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
LT3313829T (lt) 2015-06-29 2024-08-12 Acuitas Therapeutics Inc. Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3397613A1 (en) 2015-12-30 2018-11-07 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
TWI773666B (zh) 2016-03-30 2022-08-11 美商英特利亞醫療公司 Crispr/cas 組分之脂質奈米粒子調配物
CA3027312A1 (en) 2016-06-13 2017-12-21 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11583504B2 (en) * 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
MX2019005470A (es) 2016-11-10 2019-11-21 Translate Bio Inc Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm.
WO2018089801A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
US11260149B2 (en) * 2017-05-28 2022-03-01 Niloofar Eslahi Hydrogel for cartilage tissue regeneration
US11918653B2 (en) * 2017-12-22 2024-03-05 Dompé Farmaceutici S.P.A. Triglyceride otic formulations and uses thereof
MX2020011166A (es) 2018-04-25 2022-10-19 Ethris Gmbh Agentes crioprotectores para formulaciones en forma de particulas.

Similar Documents

Publication Publication Date Title
JP2023513043A5 (https=)
JP2022542562A5 (https=)
BR102021014044A2 (https=)
CN306752364S (https=)
CN306761980S (https=)
CN305535557S (https=)
CN305534785S (https=)
CN305534501S (https=)
CN305534304S (https=)
CN305537042S (https=)
CN305533764S (https=)
CN305530334S (https=)
CN305529596S (https=)
CN305537283S (https=)
CN306872608S (https=)
CN306750694S (https=)
CN306761522S (https=)
CN306760852S (https=)
CN306759460S (https=)
CN306758586S (https=)
CN306757827S (https=)
CN306755711S (https=)
CN306754366S (https=)
CN306753680S (https=)
CN305531766S (https=)